Detalhe da pesquisa
1.
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ann Oncol
; 34(8): 681-692, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37211045
2.
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
Ann Oncol
; 28(6): 1280-1287, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28368437